SavedAdd your journal

Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 5

Clinical experience in the treatment of spinal cord tumors with cyberknife® fractionated stereotactic radiotherapy

Suheyla Aytac Arslan
Gonca Altinisik Inan
Gulhan Guler Avci
Yildiz Guney
Mehtap Coskun Breuneval
Pages
884–887
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, well-designed studies with longer follow-up and a large number of patients are warranted

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of the study is to evaluate the efficacy and safety of Cyberknife® fractionated stereotactic radiotherapy (FSRT) in spinalcord tumors.
📊
Key Findings & Data:The secondary aim is to present short-term local control of the patients with spinal cord tumors.Materials and Methods: Ten patients with spinal cord tumors who underwent FSRT between January 2010 and May 2014 wereretrospectively analyzed.
💡
Conclusion & Impact:However, well-designed studies with longer follow-up and a large number of patients are warranted
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of the study is to evaluate the efficacy and safety of Cyberknife® fractionated stereotactic radiotherapy (FSRT) in spinalcord tumors. The secondary aim is to present short-term local control of the patients with spinal cord tumors.Materials and Methods: Ten patients with spinal cord tumors who underwent FSRT between January 2010 and May 2014 wereretrospectively analyzed. FSRT was administered in a median dose of 20 Gy (range, 16-40 Gy) in a median 5 fractions (range, 4-6 fractions). Radiological / pathological diagnoses of the patients are meningioma (n = 3), schwannoma (n = 1), neurofibroma (n = 1), hemangioblastoma (n = 1), chordoma (n = 1), recurrent medulloblastoma (n = 1), recurrent ependymoma (n = 2). Results: The median age was 57 years (range, 22-84 years). The median tumor volume was 3.3 cm3 (range, 1.8- 74 cm3). Tumorlocalization was cervical in six cases, lumbar in three cases, and thoracic in one case. The median follow-up time was 13 months (range, 3-48 months). Clinical improvement was observed by FSRT in all patients except the three cases. Tumor control (no progression) was achieved in all cases. Radiologically, 6 patients were stable, 2 patients had complete and 1 patient had a partial response. No acute toxicity due to FSRT was observed in any cases.Conclusion: Stereotactic radiosurgery /radiotherapy provides acceptable toxicity and excellent local control results in patients withspinal cord tumors. However, well-designed studies with longer follow-up and a large number of patients are warranted

🔖

Cite This Article

Arslan, S. A., Inan, G. A., Avci, G. G., Guney, Y., Breuneval, M. C. (2022). Clinical experience in the treatment of spinal cord tumors with cyberknife® fractionated stereotactic radiotherapy. Annals of Medical Research, Cilt: 28 - Sayı: 5, 884–887. https://ajindex.com/articles/446257

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Grimm S, Chamberlain MC. Adult primary spinal cord tumors. Expert Rev Neurother 2009;9:1487-95
  2. Sioka C, Kyritsis AP. Chemotherapy, hormonal therapy and immunotherapy for recurrent meningiomas. J Neurooncol 2009;92:1-6
  3. Adler JR Jr, Chang SD, Murphy MJ, et al. The Cyberknife: A frameless robotic system for radiosurgery. Stereotact Funct Neurosurg 1997;69:124-8
  4. Sahgal A, Ames C, Chou D, et al. Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys 2009;74:723-31
  5. Sahgal A, Chou D, Ames C, et al. Image-guided robotic stereotactic body radiotherapy for benign spinal tumors: the University of California San Francisco preliminary experience. Technol Cancer Res Treat 2007;6:595-604
  6. Sahgal A, Larson DA, Chang EL. Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 2008;71:652-65
  7. Ryu SI, Chang SD, Kim DH, et al. Image-guided hypo- fractionated stereotactic radiosurgery to spinal lesions. Neurosurgery 2001;49:838-46
  8. Gerszten PC, Welch WC. Cyberknife radiosurgery for metastatic spine tumors. Neurosurg Clin N Am 2004;15:491-501
  9. Dodd RL, Ryu MR, Kamnerdsupaphon P et al. CyberKnife radiosurgery for benign intradural extramedullary spinal tumors. Neurosurgery 2006;58:674-85
  10. Gerszten PC, Burton SA, Ozhasoglu C et al. Radiosurgery for benign intradural spinal tumors. Neurosurgery 2008;62:887-95
  11. Chang UK, Rhee CH, Youn SM et al. Radiosurgery using the Cyberknife for benign spinal tumors: Korea Cancer Center Hospital experience. J Neurooncol 2011;101:91-9
  12. Kufeld M, Wowra B, Muacevic A et al. Radiosurgery of spinal meningiomas and schwannomas. Technol Cancer Res Treat. 2012;11:27-34
  13. Hwang L, Okoye CC, Patel RB et al. Stereotactic body radiotherapy for benign spinal tumors: Meningiomas, schwannomas, and neurofibromas. J Radiosurg SBRT 2019;6:167-77
  14. Shin DW, Sohn MJ, Kim HS, et al. Clinical analysis of spinal stereotactic radiosurgery in the treatment of neurogenic tumors. J Neurosurg Spine 2015;23:429- 37
  15. Kalash R, Glaser SM, Flickinger JC, et al. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate? J Neurosurg Spine 2018;29:220-5
  16. Chin AL, Fujimoto D, Kumar KA et al. Long-Term Update of Stereotactic Radiosurgery for Benign Spinal Tumors. Neurosurgery 2019;85:708-16